The highly stable synthetic lung surfactant formulation developed by Molecular Express has comparable or superior in vivo activity compared to other lung surfactant currently on the market. The formulation has great potential for lung disease and lung injury therapies.

Our research explores the molecular pathways that drive regeneration, inspired by highly regenerative animals like salamanders. By decoding these conserved mechanisms across species, we aim to activate latent regenerative capabilities in humans.

While humans can regenerate fingertip tissue, broader applications in tissue and organ repair remain untapped. Our work focuses on genetic and biochemical strategies to address critical areas:

• Wound Healing: Ideal for His-tagged proteins, providing high specificity and yield.
• Congenital Malformations: Developing therapies for developmental corrections.
• Aging and Tissue Damage: Mitigating age-related deterioration and promoting repair.

Breast cancer treatment has made strides, yet the five-year survival rate for advanced stages remains concerning. To tackle this challenge, we are collaborating with researchers to develop a formulation of a unique molecule derived from snake venom, known for its potent antiangiogenic properties.

Our goal is to confirm that this formulation can be produced using standard commercial manufacturing methods without compromising efficacy.

Our program aims to develop a combination therapy utilizing a novel molecule from snake venom that has shown promising anti-tumor effects. By integrating this unique approach, we seek to enhance treatment efficacy and improve survival rates for patients with advanced prostate cancer.

Investigating the use of phage-displayed Randomized Repeat Protein (RRP) libraries in partnership with researchers, we aim to develop novel ligands for the Prostate-Specific Membrane Antigen (PSMA). This project focuses on demonstrating the potential for rapid selection of PSMA ligands, offering significant advantages over traditional monoclonal antibodies for targeted therapies.